Jordan J. Feld, MD, MPH - 1/24/2017
Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
HBV reactivation is a potentially serious complication of immunosuppressive therapy. Fortunately, if properly identified and managed, it is also an almost entirely avoidable complication of immunosuppressive therapy. So why do fatal cases of HBV reactivation continue to occur?
Continue reading at Clinical Care Options
Free registration required
Continue reading at Clinical Care Options
Free registration required
No comments:
Post a Comment